Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $4.30, $0.10 better than the analyst estimate of $4.20. Revenue for the quarter came in at $932.9 million versus the consensus estimate of $902.46 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2022 EPS of $16.70-$17.71, versus the consensus of $17.09. Jazz Pharmaceuticals sees FY2022 revenue of $3.5-3.7 billion, versus the consensus of $3.6 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.